Abstract
1. The population pharmacokinetics of lisinopril were investigated using data collected from two multicentre trials of lisinopril in the treatment of hypertension in elderly patients (n = 40) and patients with renal disease (n = 20). 2. Lisinopril was started at doses of 2.5-5 mg daily and increased at 2-4 weekly intervals as required for control of blood pressure. Steady-state concentration-time profiles were measured after at least 2 weeks at a constant dose. 3. All concentration-time data were analysed simultaneously using the program NONMEM and the influence of clinical factors on clearance/F and volume of distribution/F was tested. 4. Clearance was significantly influenced by creatinine concentration, age, weight and cardiac failure. No clinical features tested were found to influence volume of distribution. 5. The influence of renal function and cardiac failure on lisinopril clearance has been confirmed using a population pharmacokinetic analysis technique.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ajayi A. A., Campbell B. C., Kelman A. W., Howie C., Meredith P. A., Reid J. L. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res. 1985;5(6):419–427. [PubMed] [Google Scholar]
- Dickstein K., Aarsland T., Tjelta K., Cirillo V. J., Gomez H. J. A comparison of hypotensive responses after oral and intravenous administration of enalapril and lisinopril in chronic heart failure. J Cardiovasc Pharmacol. 1987 Jun;9(6):705–710. doi: 10.1097/00005344-198706000-00011. [DOI] [PubMed] [Google Scholar]
- Francis R. J., Brown A. N., Kler L., Fasanella d'Amore T., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol. 1987 Jan;9(1):32–38. [PubMed] [Google Scholar]
- Gautam P. C., Vargas E., Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol. 1987 Nov;39(11):929–931. doi: 10.1111/j.2042-7158.1987.tb03130.x. [DOI] [PubMed] [Google Scholar]
- Millar J. A., Derkx F. H., McLean K., Reid J. L. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982 Sep;14(3):347–355. doi: 10.1111/j.1365-2125.1982.tb01990.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sheiner L. B., Rosenberg B., Marathe V. V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 Oct;5(5):445–479. doi: 10.1007/BF01061728. [DOI] [PubMed] [Google Scholar]
- Thomson A. H., Whiting B. Population pharmacokinetics of lisinopril in hypertensive patients. Gerontology. 1987;33 (Suppl 1):17–23. doi: 10.1159/000212915. [DOI] [PubMed] [Google Scholar]
- Till A. E., Gomez H. J., Hichens M., Bolognese J. A., McNabb W. R., Brooks B. A., Noormohamed F., Lant A. F. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos. 1984 Jul-Sep;5(3):273–280. doi: 10.1002/bdd.2510050309. [DOI] [PubMed] [Google Scholar]
- Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Schaik B. A., Geyskes G. G., Boer P. Lisinopril in hypertensive patients with and without renal failure. Eur J Clin Pharmacol. 1987;32(1):11–16. doi: 10.1007/BF00609951. [DOI] [PubMed] [Google Scholar]